Angiogenesis and angiogenic inhibitors in renal cell carcinoma

Current Urology Reports

Volumn 9, Issue 1, 2008, Pages 26-33

  Sawhney, Rishi ^b   Kabbinavar, Fairooz ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; AMG 102; AMG 386; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PLACEBO; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VATALANIB; VOLOCIXIMAB;

ANGIOGENESIS; ASTHENIA; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG TOLERABILITY; FATIGUE; GENE MUTATION; HAND FOOT SYNDROME; HEART MUSCLE ISCHEMIA; HEMOPTYSIS; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LYMPHOCYTOPENIA; METASTASIS; NAUSEA; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 38349077490     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-008-0007-2     Document Type: Review

References (67)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
2. Chow W-H, Devesa SS, Warren JL, Fraumeni JF: Rising incidence of renal cell cancer in the United States. JAMA 1999, 281:1628-1631.
3. Lam JS, Leppert JT, Belldegrun AS, Figlin RA: Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 2005, 23:202-212.
4. Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N Engl J Med 1996, 335:865-875.
5. Janzen NK, Kim HL, Figlin RA, Belldegrun AS: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003, 30:843-852.
6. Amato RJ: Chemotherapy for renal cell carcinoma, Semin Oncol 2000, 27:177-186.
7. Yagoda A, Petrylak D, Thompson S: Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993, 20:303-321.
8. Rosenberg SA, Yang JC, Topalian SL, et al.: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994, 271:907-913.
9. Fyfe GA, Fisher RI, Rosenberg SA, Sznol M: Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 1996, 14:2410-2411.
10. Fossa SD: Interferon in metastatic renal cell carcinoma. Semin Oncol 2000, 27:187-193.
11. Latif F, Tory K, Gnarra J, et al.: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993, 260:1317-1320.
12. Knudson AG Jr: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971, 68:820-823.
13. Herman JG, Latif F, Weng Y, et al.: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994, 91:9700-9704.
14. Gnarra JR, Tory K, Weng Y, et al.: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994, 7:85-90.
15. Clifford SC, Prowse AH, Affara NA, et al.: Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 1998, 22:200-209.
16. Kondo K, Yao M, Yoshida M, et al.: Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer 2002, 34:58-68.
17. Leung SK, Ohh M: Playing tag with HIF: the VHL story. J Biomed Biotechnol 2002, 2:131-135.
18. Iliopoulos O, Levy AP, Jiang C, et al.: Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 1996, 93:10595-10599.
19. Gnarra JR, Zhou S, Merrill MJ, et al.: Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 1996, 93:10589-10594.
20. Shweiki D, Itin A, Soffer D, et al.: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359:843-845.
21. Lee JS, Kim HS, Jung JJ, et al.: Expression of vascular endothelial growth factor in renal cell carcinoma and the relation to angiogenesis and p53 protein expression. J Surg Oncol 2001, 77:55-60.
22. Takahashi A, Sasaki H, Kim SJ, et al.: Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 1994, 54:4233-4237.
23. Igarashi H, Esumi M, Ishida H, et al.: Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma. Cancer 2002, 95:47-53.
24. Na X, Wu G, Ryan CK, et al.: Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol 2003, 170:588-592.
25. Ostman A, Heldin CH: Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv Cancer Res 200, 80:1-38.
26. Pore N, Liu S, Haas-Kogan DA, et al.: PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Res 2003, 63:236-241.
27. Rak J, Kerbel RS: Ras regulation of vascular endothelial growth factor and angiogenesis. Methods Enzymol 2001, 333:267-283.
28. Hilger RA, Scheulen ME, Strumberg D: The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 2002, 25:511-518.
29. Oka H, Chatani Y, Hoshino R, et al.: Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 1995, 55:4182-4187.
30. Chen J, Fujii K, Zhang L, et al.: Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc Natl Acad Sci USA 2001, 98:7783-7788.
31. Eisenmann KM, VanBrocklin MW, Staffend NA, et al.: Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad. Cancer Res 2003, 63:8330-8337.
32. Wang HG, Rapp UR, Reed JC: Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 1996, 87:629-638.
33. Hudson CC, Liu M, Chiang GG, et al.: Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002, 22:7004-7014.
34. Mita MM, Mita A, Rowinsky EK: The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther 2003, 2:S169-S177.
35. Brenner W, Farber G, Herget T, et al.: Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Cancer 2002, 99:53-57.
36. Folkman J: The role of angiogenesis in tumor growth. Semin Cancer Biol 1992, 3:65-71.
37. Tischer E, Mitchell R, Hartman T, et al.: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991, 266:11947-11954.
38. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002, 20:4368-4380.
39. Dvorak HF, Brown LF, Detmar M, et al.: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995, 146:1029-1039.
40. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 1997, 18:4-25.
41. Watanabe Y, Lee SW, Detmar M, et al.: Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells. Oncogene 1997, 14:2025-2032.
42. Benjamin LE, Golijanin D, Itin A, et al.: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999, 103:159-165.
43. Slaton JW, Inoue K, Perrotte P, et al.: Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol 2001, 158:735-743.
44. Presta LG, Chen H, O'Connor SJ, et al.: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57:4593-4599.
45. Yang JC, Haworth L, Sherry RM, et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-434. The first paper that showed targeting VEGF in RCC had an antitumor effect using bevacizumab.
46. Escudier B, Koralewski P, et al.: A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-alpha2a vs placebo/interferon-alpha2a as first-line therapy in metastatic renal cell carcinoma. Proceedings of the American Society of Clinical Oncology Annual Meeting 2007. Alexandria, VA: American Society of Clinical Oncology; 2007, 25:3.
47. Shen BQ, Metz T, Fiebig HH, et al.: Effect of combination therapy targeting both VEGF and EGF receptor signaling pathways in human renal cell carcinoma explant models. Proc Am Assoc Cancer Res 2004 45:3007a.
48. Hainsworth JD, Sosman JA, Spigel DR, et al.: Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC). J Clin Oncol 2005, 23:7889-7896.
49. Bukowski RM, Kabbinavar F, Figlin RA, et al.: Bevacizumab with or without erlotinib in metastatic renal cell carcinoma. J Clin Oncol 2007, 25:4536-4541. The second study that confirmed the role of bevacizumab as an effective anti-VEGF drug that also had anti-RCC activity.
50. Lyons JF, Wilhelm S, Hibner B, et al.: Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001, 8:219-225.
51. Wilhelm SM, Carter C, Tang L, et al.: BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
52. Strumberg D, Richly H, Hilger RA, et al.: Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005, 23:965-972.
53. Ratain MJ, Flaherty KT, Stadler WM, et al.: Preliminary antitumor activity of BAY 43 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). J Clin Oncol 2006, 24:2505-2512.
54. Escudier B, Eisen T, Stadler WM, et al.: TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134. An important study that has given us an effective option for cytokine refractory patients with RCC.
55. Mendel DB, Laird AD, Xin X, et al.: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9:327-337.
56. Raymond E, Faivre S, Vera K, et al.: Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced cancers [abstract 769]. Proc Am Soc Clin Oncol 2003, 22:192.
57. Motzer RJ, Michaelson MD, Redman BG, et al.: SU011248, a novel tyrosine kinase inhibitor, shows anti-tumor activity in second-line therapy for patients with metastatic renal cell carcinoma: results of a phase II trial. J Clin Oncol 2004, 23:4500.
58. Motzer RJ, Hutson TE, Tomczak P, et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124. This practice-altering study on sunitinib changed the way RCC is treated.
59. Wood JM, Bold G, Buchdunger E, et al.: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000, 60:2178-2189.
60. Drevs J, Hofmann I, Hugenschmidt H, et al.: Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 2000, 60:4819-4824.
61. George D, Michaelson MD, Oh WK, et al.: Phase I study of PTK787/ZK222584 (PTK/ZK) in metastatic renal cell carcinoma. J Clin Oncol 2003, 22:5039.
62. Ramakrishnan V, Bhaskar V, Law DA, et al.: Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol 2006, 5:273-286.
63. Rini B, Rixe O, Bukowski R, et al.: AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). Proceedings of the American Society of Clinical Oncology Annual Meeting 2006. Alexandria, VA: American Society of Clinical Oncology; 2005, 23:4509.
64. Amgen: Pipeline. AMG 102. Available at http://www.amgen.com/ science/pipe_AMG102.html. Accessed October 2007.
65. Dawson D, Pearce S, Zhong R, et al.: CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997, 138:707-717.
66. Hoekstra R, de Vos FY, Eskens FA, et al.: Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J Clin Oncol 2005, 23:5188-5197.
67. Amgen: Pipeline. AMG 386. Available at http://www.amgen.com/ science/pipe_AMG386.htmlext. Accessed October 2007.